A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34182
Abstract: Patients with refractory central nervous system leukemia (CNSL) have a dismal prognosis and lack effective therapy. Case reports have shown that sorafenib is effective against brain metastases, including leukemia. read more here.
Keywords: system leukemia; central nervous; refractory central; phase study ... See more keywords